Desentum, an Espoo, Finland-based biopharmaceutical company advancing an allergy vaccine candidate, raised 8 M€ in funding.
The round was arranged by Springvest Oyj.
The company intends to use the funds for funding further clinical development, R&D of new hypoallergens and business development.
Led by Pekka Mattila, CEO, Desentum develops novel immunotherapeutic hypoallergens, so called allergy vaccines. The hypoallergens are biotechnologically produced, modified allergen proteins aimed for improving the efficiency of allergen immunotherapy while also reducing the time required for treatment. The lead product candidate, birch pollen hypoallergen DM-101, has passed a First-in-Human clinical study. In the study, DM-101 was found to be safe and well tolerated with the highest of the tested dosing regimens, and immunological marker results indicated a favourable change in the markers associated with a protective response.
Founded in 2011, Desentum is a spin-off company from VTT Technical Research Centre of Finland Ltd.
FinSMEs
21/01/2022